Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial.

Area of Science:

• Pulmonary Medicine
• Clinical Trial Methodology
• Respiratory Disease Research

Background:

• Chronic obstructive pulmonary disease (COPD) management relies on lung function, exacerbations, and health status assessments.
• Current measures may not fully capture the holistic clinical picture of COPD progression.
• A novel composite endpoint was investigated to better assess clinically important deterioration (CID) in COPD.

Purpose of the Study:

• To evaluate a composite endpoint for assessing clinically important deterioration (CID) in COPD clinical trials.
• To determine if a composite endpoint provides a more comprehensive assessment of COPD progression and treatment response.

Main Methods:

• Post hoc analysis of 5652 patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2-4 COPD from the 4-year UPLIFT study.
• The composite endpoint comprised time to first confirmed decrease in trough forced expiratory volume in 1 second (FEV₁) ≥100 mL, confirmed increase in St. George's Respiratory Questionnaire (SGRQ) total score ≥4 units, or moderate/severe exacerbation.
• Patients received either tiotropium 18 μg or placebo.

Main Results:

• Over 80% of patients experienced CID, with consistent incidence across GOLD subgroups.
• Deteriorations in FEV₁ and SGRQ were largely sustained throughout the study.
• Patients with CID had a higher likelihood of subsequent exacerbation (HR 1.79) or death (HR 1.21) by Month 6.
• The composite endpoint demonstrated responsiveness to bronchodilator treatment.

Conclusions:

• Composite endpoints offer valuable additional information on COPD progression in clinical trials.
• This composite endpoint holistically assesses clinically important deterioration.
• The findings support the utility of composite endpoints for evaluating treatment effects in COPD studies.